Metastatic Colorectal Cancer
The sponsor’s clinical research is centered on metastatic colorectal cancer, with a strong focus on treatment strategies for patients with advanced disease and prior treatment exposure.
- RAS/BRAF wild-type disease
- Second-line and later-line treatment
- Biomarker-selected patient populations
Its studies address molecularly defined subgroups within metastatic colorectal cancer, reflecting a sustained interest in precision-oriented oncology care.
EGFR-Targeted Therapy
Another major area of interest is EGFR-directed treatment, particularly the use of cetuximab across multiple treatment settings in colorectal cancer.
- cetuximab-based regimens
- Comparison with bevacizumab-based approaches
- Continuation and rechallenge strategies
The funded trials explore how EGFR inhibition can be integrated into treatment sequences for patients with molecularly selected disease.
Immunotherapy Combinations
The sponsor also supports research involving immunotherapy combinations in pre-treated colorectal cancer, with attention to pairing immune-based agents with targeted therapy.
- avelumab plus cetuximab
- Rechallenge approaches
- Pre-treated patient cohorts
These studies examine the role of immune modulation in patients whose tumors retain RAS/BRAF wild-type status.
Treatment Sequencing and Response Assessment
Research activity extends to the evaluation of treatment sequencing, with interest in how different therapeutic lines influence response in advanced colorectal cancer.
- Objective Response Rate
- Overall Survival
- Multi-line therapy planning
The clinical portfolio reflects a focus on response-driven decision-making in advanced gastrointestinal oncology.
